A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.
Adult
Antimalarials
/ therapeutic use
Asymptomatic Diseases
Azithromycin
/ therapeutic use
Chemoprevention
/ methods
Drug Combinations
Erythrocytes
/ drug effects
Female
Gestational Age
Humans
Live Birth
Malaria, Falciparum
/ drug therapy
Malaria, Vivax
/ drug therapy
Papua New Guinea
Parasitemia
/ drug therapy
Plasmodium falciparum
/ drug effects
Plasmodium vivax
/ drug effects
Pregnancy
Pyrimethamine
/ therapeutic use
Quinolines
/ therapeutic use
Random Allocation
Severity of Illness Index
Stillbirth
Sulfadoxine
/ therapeutic use
azithromycin
efficacy
malaria
piperaquine
pregnancy
tolerability
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
10
02
2019
accepted:
26
07
2019
pubmed:
14
8
2019
medline:
4
8
2020
entrez:
14
8
2019
Statut:
epublish
Résumé
Emerging malaria parasite sulfadoxine-pyrimethamine (SP) resistance has prompted assessment of alternatives for intermittent preventive treatment in pregnancy (IPTp). The objective was to evaluate the tolerability and prophylactic efficacy of azithromycin (AZ) plus piperaquine (PQ) in pregnant women in Papua New Guinea. The study was an open-label, randomized, parallel-group trial. A total of 122 women (median gestation, 26 weeks [range, 14 to 32 weeks]) were randomized 1:1 to three daily doses of 1 g AZ plus 960 mg PQ tetraphosphate or single-dose SP (4,500 mg sulfadoxine plus 225 mg pyrimethamine), based on computer-generated block randomization. Tolerability was assessed to day 7, and efficacy was assessed to day 42 (when participants were returned to usual care) and at delivery. Data for 119 participants (AZ-PQ,
Identifiants
pubmed: 31405866
pii: AAC.00302-19
doi: 10.1128/AAC.00302-19
pmc: PMC6761509
pii:
doi:
Substances chimiques
Antimalarials
0
Drug Combinations
0
Quinolines
0
fanasil, pyrimethamine drug combination
37338-39-9
Azithromycin
83905-01-5
Sulfadoxine
88463U4SM5
piperaquine
A0HV2Q956Y
Pyrimethamine
Z3614QOX8W
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
Am J Trop Med Hyg. 2010 Dec;83(6):1212-20
pubmed: 21118924
Bull World Health Organ. 2017 Oct 1;95(10):695-705B
pubmed: 29147042
Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006688
pubmed: 21328286
Malar J. 2014 Apr 16;13:145
pubmed: 24739250
Expert Opin Drug Metab Toxicol. 2011 Sep;7(9):1153-67
pubmed: 21736423
J Antimicrob Chemother. 2001 Jan;47(1):61-6
pubmed: 11152432
Drugs. 2005;65(1):75-87
pubmed: 15610051
J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1522-7
pubmed: 11185676
Aust N Z J Obstet Gynaecol. 2019 Jun;59(3):394-402
pubmed: 30209806
Br J Clin Pharmacol. 2016 Jul;82(1):199-212
pubmed: 26889763
Lancet Glob Health. 2015 Nov;3(11):e672
pubmed: 26475008
Malar J. 2013 Apr 11;12:122
pubmed: 23577619
J Antimicrob Chemother. 2014 Feb;69(2):323-30
pubmed: 24126794
Trop Med Int Health. 2013 Apr;18(4):386-97
pubmed: 23432801
Lancet. 2004 Jan 3;363(9402):9-17
pubmed: 14723987
N Engl J Med. 2016 Mar 10;374(10):928-39
pubmed: 26962728
Matern Child Nutr. 2016 Oct;12(4):699-712
pubmed: 26373537
J Infect Dis. 2014 Aug 15;210(4):585-92
pubmed: 24652498
Am J Trop Med Hyg. 2007 Jun;76(6):997-1008
pubmed: 17556601
PLoS One. 2016 Mar 17;11(3):e0150259
pubmed: 26986471
P N G Med J. 2003 Mar-Jun;46(1-2):8-15
pubmed: 16450779
Expert Opin Pharmacother. 2018 Nov;19(16):1779-1796
pubmed: 30289730
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1592-9
pubmed: 26711756
Expert Rev Anti Infect Ther. 2017 Apr;15(4):361-375
pubmed: 27973923
P N G Med J. 2008 Mar-Jun;51(1-2):12-6
pubmed: 19999304
Niger Postgrad Med J. 2016 Apr-Jun;23(2):57-61
pubmed: 27424614
PLoS Med. 2016 Sep 13;13(9):e1002124
pubmed: 27622558
Clin Infect Dis. 2016 Feb 1;62(3):323-333
pubmed: 26486699
PLoS One. 2016 Jun 21;11(6):e0157045
pubmed: 27326859
N Engl J Med. 2008 Dec 11;359(24):2545-57
pubmed: 19064624
Clin Infect Dis. 2018 Sep 14;67(7):1079-1088
pubmed: 29547881
Lancet Infect Dis. 2007 Feb;7(2):93-104
pubmed: 17251080
PLoS One. 2012;7(7):e41123
pubmed: 22829919
Pharmacol Ther. 2014 Aug;143(2):225-45
pubmed: 24631273
PLoS One. 2016 Nov 18;11(11):e0165692
pubmed: 27861509
Am J Trop Med Hyg. 2016 Jul 6;95(1):164-7
pubmed: 27215294
BMC Med. 2015 Jan 16;13:9
pubmed: 25591391
Emerg Infect Dis. 2013;19(9):
pubmed: 23969132
JAMA. 2007 Jun 20;297(23):2603-16
pubmed: 17579229
Antimicrob Agents Chemother. 2010 Jan;54(1):360-6
pubmed: 19858250
Antimicrob Agents Chemother. 2009 Oct;53(10):4368-76
pubmed: 19620325
Lancet. 2015 Dec 19;386(10012):2507-19
pubmed: 26429700
Lancet Infect Dis. 2018 Apr;18(4):e119-e132
pubmed: 29395997
Lancet. 2019 Apr 6;393(10179):1428-1439
pubmed: 30910321
Malar J. 2008 Dec 16;7:255
pubmed: 19087267
Lancet. 2015 Dec 19;386(10012):2454-6
pubmed: 26429701
Antimicrob Agents Chemother. 2015 Jul;59(7):4260-71
pubmed: 25963981
Eur J Clin Pharmacol. 2012 May;68(5):479-503
pubmed: 22105373